HALEOS LABS LIMITED
All news and filings related to HALEOS LABS LIMITED.
View all news & filings- Low impact
Haleos Labs Announces 20th AGM on Sep 30, 2026; Dividend Record Date Sep 23
Haleos Labs will hold its 20th AGM on September 30, 2026, via video conference. The record date for the 2025-26 dividend and e-voting cut-off is September 23, 2026. E-voting is open from September 26 to September 29, 2026. The Annual Report and AGM Notice are available online.
Read the summary - Low impact
Haleos Labs Limited Announces 20th AGM; Recommends Dividend
Haleos Labs Limited will hold its 20th AGM on September 30, 2026, via VC. The Board recommended a dividend of ₹1.50 per equity share for FY25-26. Remote e-voting is available from September 26-29, 2026. Unclaimed dividends from FY18-19 will be transferred to IEPF in FY26-27.
Read the summary - Medium impact
Haleos Labs to hold 20th AGM on Sep 30, 2026; proposes ₹1.50 dividend
Haleos Labs will hold its 20th AGM on September 30, 2026, via video conference. The agenda includes adopting FY26 financial statements and declaring a ₹1.50 per share dividend. The meeting also covers director re-appointments, auditor appointments, and revision of the Managing Director's remuneration.
Read the summary - Low impact
Haleos Labs Announces 20th AGM on Sep 30, 2026, with E-voting from Sep 26
Haleos Labs Limited will hold its 20th AGM on September 30, 2026, via Video Conferencing. E-voting begins September 26 and ends September 29. The cut-off for dividend entitlement is September 23. Central Depository Services (India) Ltd and Mr. C. Sudhir Babu have been appointed for e-voting and scrutiny.
Read the summary - Low impact
Haleos Labs Sets Record Date for Dividend Payout and 20th AGM on Sep 23 & Sep 30, 2026
Haleos Labs Limited has fixed Wednesday, September 23, 2026, as the record date for its 2025-26 dividend. The 20th AGM is scheduled for September 30, 2026. Dividend payments will be electronic only.
Read the summary - Medium impact
Haleos Labs Shareholders Approve Director Reappointment & RPTs; Reject Remuneration
Haleos Labs shareholders approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director and material related party transactions for 2026-27. However, the resolution for managerial remuneration to Executive Directors was not approved. The postal ballot voting concluded on August 28, 2026.
Read the summary - Low impact
Haleos Labs: TDS on Dividend Explained; Shareholders Must Submit Documents by Sept 25
Haleos Labs Limited announced TDS procedures for its FY25-26 final dividend of ₹1.50 per share. Shareholders must submit required documents and declarations by September 25, 2026. The dividend is subject to AGM approval and will be paid to shareholders on record as of September 23, 2026.
Read the summary - Low impact
Haleos Labs Publishes Q1 FY26 Financial Results in Newspapers
Haleos Labs published its unaudited financial results for Q1 FY26 on August 7, 2026. Revenue from operations stood at ₹729.42 crore (standalone) and ₹825.46 crore (consolidated). Net profit after tax was ₹18.40 crore (standalone) and ₹43.82 crore (consolidated).
Read the summary - Low impact
Haleos Labs Subsidiary Appoints Cost Auditors and Nominee Director
Haleos Labs subsidiary, Mahi Drugs Private Limited, appointed Annapragada & Co. as Cost Auditors for FY2026-27. Mr. Vincent P. Asaro was appointed as Nominee Director, effective August 5, 2026, nominated by ChemWerth Inc.
Read the summary - Medium impact
Haleos Labs Reappoints Two Independent Directors for Five-Year Term
Haleos Labs Limited reappointed Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors. Their second term of five years begins November 13, 2026, pending shareholder approval. Both directors bring extensive experience in public service and critical care medicine, respectively.
Read the summary - Medium impact
Haleos Labs Board Approves Q1FY27 Results, Reappoints Directors
Haleos Labs reported Q1FY27 results with standalone revenue at ₹67.83 crore and profit at ₹3.24 crore. Consolidated revenue was ₹72.94 crore with profit at ₹1.88 crore. The board approved re-appointment of two Independent Directors for a 5-year term and the 20th AGM on September 30, 2026.
Read the summary - Low impact
Haleos Labs publishes Newspaper Advertisement for Postal Ballot
Haleos Labs Limited published a newspaper advertisement on July 30, 2026, regarding a Postal Ballot conducted via remote e-voting. The voting period is from July 30, 2026, to August 28, 2026. Results will be announced on August 31, 2026. A 'Special Window' has also been publicized as per SEBI circular.
Read the summary - Medium impact
Haleos Labs seeks shareholder approval via postal ballot for director reappointment and RPTs
Haleos Labs is conducting a postal ballot for shareholders to approve the reappointment of Mrs. Sudeepthi Gopineedi as Whole-Time Director for five years. Shareholders will also vote on managerial remuneration and material related party transactions. E-voting is open from July 30 to August 28, 2026.
Read the summary - Medium impact
Haleos Labs Seeks Shareholder Approval Via Postal Ballot for Director Reappointment and Remuneration
Haleos Labs will conduct a postal ballot for shareholders to approve Mrs. Sudeepthi Gopineedi's reappointment as Whole-time Director and managerial remuneration. Shareholders will also vote on related party transactions. E-voting starts July 30, 2026, and ends August 28, 2026. Results will be declared on August 31, 2026.
Read the summary - Low impact
Haleos Labs Files SEBI Compliance Certificate for Q1 FY27
Haleos Labs Limited submitted a compliance certificate for the quarter ending June 30, 2026, as per SEBI regulations. The RTA confirmed timely dematerialization and processing of securities.
Read the summary - Low impact
Haleos Labs Limited: Trading Window Closed from July 1, 2026, for Q2 FY27 Results
Haleos Labs Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter ending June 30, 2026. The exact date for the board meeting to consider these results will be announced later.
Read the summary - Low impact
Haleos Labs to Transfer Unclaimed Shares to IEPF by Nov 5, 2026
Haleos Labs Limited is transferring unclaimed shares from FY 2018-19 to the IEPF suspense account. Shareholders must claim unpaid dividends by November 5, 2026, to prevent share transfer. Public notices have been issued, and details are on the company website.
Read the summary - Low impact
Haleos Labs Limited: Promoter Group Reports Zero Share Encumbrance for FY26
Haleos Labs Limited's promoter and promoter group reported zero share encumbrance for the financial year ended March 31, 2026. The disclosure covers individuals and entities including TVVSN Murthy and M/s Potluri Laboratories Private Limited.
Read the summary - Low impact
Haleos Labs Reconstitutes Board Sub-Committees Post-Board Meeting
Haleos Labs Limited reconstituted its board sub-committees following a meeting on May 29, 2026. New compositions were announced for the Audit, Nomination and Remuneration, CSR, and Stakeholders Relationship committees, with changes in chairpersons and members.
Read the summary - Low impact
Haleos Labs Limited Publishes Financial Results in Newspapers
Haleos Labs Limited has published its financial results for the quarter and year ended March 31, 2026. The results were advertised in Financial Express and Telugu Prabha on May 31, 2026. The information is also available on the company's website.
Read the summary - Medium impact
Haleos Labs Appoints Suryanarayana & Suresh as Statutory Auditors for 5 Years
Haleos Labs Limited has appointed Suryanarayana & Suresh as statutory auditors for a five-year term, starting from the 20th AGM until the 25th AGM. Annapragada & Co. has been reappointed as Cost Auditors for FY 2026-27. Both appointments are subject to shareholder approval.
Read the summary - Low impact
Haleos Labs Resignation of Independent Director Mrs. Sundaramma Patibandla
Mrs. Sundaramma Patibandla resigned as Independent Director of Haleos Labs Limited effective May 29, 2026, due to professional commitments. She also stepped down from board committees.
Read the summary - Medium impact
Haleos Labs Reappoints Sudeepthi Gopineedi as Whole-Time Director for 5 Years
Haleos Labs Limited has reappointed Mrs. Sudeepthi Gopineedi as Whole-Time Director for another 5-year term starting September 2, 2026. The Board approved the reappointment on May 29, 2026, pending shareholder approval.
Read the summary - Medium impact
Haleos Labs Declares ₹1.50 Dividend; Approves FY26 Financials
Haleos Labs approved audited standalone and consolidated financial results for FY26. A dividend of ₹1.50 per share was recommended. Mrs. Sundaramma Patibandla resigned as Independent Director. Mrs. Sudeepthi Gopineedi was reappointed as Whole-time Director. New statutory and cost auditors were approved, subject to shareholder consent.
Read the summary - Medium impact
Haleos Labs declares ₹1.50 dividend, approves FY26 results, director resignation
Haleos Labs approved audited standalone and consolidated financial results for FY26 ending March 31, 2026. A dividend of ₹1.50 per share was recommended. Mrs. Sundaramma Patibandla resigned as Independent Director. Mrs. Sudeepthi Gopineedi was reappointed as Whole-time Director for five years.
Read the summary - Low impact
Haleos Labs Launches 'Saksham Niveshak' Campaign for KYC and Dividend Updates
Haleos Labs launches 'Saksham Niveshak' campaign (April 1 - July 9, 2026) to update shareholder KYC, bank details, and nominations. Future dividends will be paid electronically only, discontinuing dividend warrants from November 18, 2025. Shareholders must update details to receive payments.
Read the summary - Medium impact
Haleos Labs: Credit Ratings Reaffirmed by Infomerics
Haleos Labs' credit ratings reaffirmed by Infomerics. Long-term rating: IVR BBB/Positive, Short-term: IVR A3+. Total bank facilities: ₹116.01 Cr. Mahi Drugs' long-term rating: IVR BB+/Stable. Total bank facilities: ₹20.75 Cr. Ratings valid until May 20, 2027.
Read the summary - Medium impact
Haleos Labs shareholders approve corporate guarantee for subsidiary's borrowings
Haleos Labs shareholders approved issuing a corporate guarantee for subsidiary Mahi Drugs Private Limited's borrowings. The resolution passed with 99.99% of votes in favor. The postal ballot concluded on April 29, 2026.
Read the summary - Low impact
Haleos Labs Limited: No Shares Encumbered by Promoters in FY26
Haleos Labs Limited announced that its promoters and promoter groups have not encumbered any shares during the financial year ended March 31, 2026. This disclosure covers all listed promoter and promoter group entities.
Read the summary - Low impact
Haleos Labs Files SEBI Compliance Certificate for Q4 FY26
Haleos Labs Limited filed a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The RTA confirmed timely dematerialization and record updates for securities.
Read the summary - Low impact
Haleos Labs Limited: Suresh Babu Potluri Confirms Reclassification Compliance
Suresh Babu Potluri confirms compliance with SEBI reclassification rules for Haleos Labs Limited. He and related parties hold less than 10% voting rights, do not control the company, and are not key managerial personnel. He will continue to comply with regulations for at least three years.
Read the summary - Low impact
Haleos Labs Publishes Newspaper Ad for Postal Ballot, Announces Special Window
Haleos Labs Limited published newspaper advertisements on March 31, 2026, regarding a postal ballot conducted via remote e-voting. The company also announced the opening of a "Special window" as per SEBI guidelines. This action follows earlier intimations on February 11 and March 26, 2026.
Read the summary - Low impact
Haleos Labs Updates Contact Email ID and Website Post Name Change
Haleos Labs Limited has updated its official contact email IDs to info@haleoslabs.com and cs@haleoslabs.com, and its website to www.haleoslabs.com. These changes follow the company's name change from SMS Lifesciences India Limited.
Read the summary - Medium impact
Haleos Labs Seeks Shareholder Approval for ₹20 Crore Corporate Guarantee for Subsidiary
Haleos Labs is seeking shareholder approval for a ₹20 Crore Corporate Guarantee for its subsidiary, Mahi Drugs Private Limited, to secure an External Commercial Borrowing facility. The remote e-voting period is from March 31 to April 29, 2026, with results announced on May 1, 2026. This is classified as a Material Related Party Transaction.
Read the summary - Medium impact
Haleos Labs to seek member approval via postal ballot for material related party transactions
Haleos Labs will seek member approval via postal ballot for issuing a corporate guarantee to RBL Bank for its subsidiary, Mahi Drugs Private Limited. E-voting starts March 31, 2026, and ends April 29, 2026. Results will be declared on May 1, 2026.
Read the summary - Low impact
Haleos Labs: Trading Window Closed from April 1, 2026 for Q4 FY26 Results
Haleos Labs Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. The board meeting date for approving results will be announced later.
Read the summary - Low impact
Haleos Labs Reopens Special Window for Physical Share Transfer Requests
Haleos Labs Limited has reopened a special window for physical share transfer requests from February 5, 2026, to February 4, 2027. This applies to transfers lodged before April 1, 2019, that were rejected or unprocessed. Shareholders must claim unclaimed dividends within seven years to avoid forfeiture to IEPFA.
Read the summary - Medium impact
Haleos Labs Q3FY26 Revenue ₹947.83 Cr, Net Profit ₹66.49 Cr
Haleos Labs reported Q3FY26 consolidated results. Revenue from operations was ₹947.83 crore, up from ₹846.01 crore year-on-year. Net Profit After Tax was ₹66.49 crore, compared to ₹48.53 crore. For the nine months, revenue was ₹2,586.55 crore and PAT was ₹174.56 crore. EPS stood at ₹21.89.
Read the summary - Medium impact
Haleos Labs Q3 FY26: Net Profit ₹540 Cr Standalone, ₹664 Cr Consolidated
Haleos Labs reported Q3 FY26 standalone net profit of ₹5.41 crore (down from ₹6.23 crore YoY) and consolidated net profit of ₹6.65 crore (up from ₹4.85 crore YoY). The company will issue a Corporate Guarantee of ₹20 crore for its subsidiary, Mahi Drugs, subject to shareholder approval via postal ballot.
Read the summary - Medium impact
Haleos Labs Collaborates With HRV Global for Orphan Drug & API Development
Haleos Labs has entered into a strategic development collaboration with HRV Global Life Sciences. The partnership aims to accelerate the development and GMP manufacturing of orphan drug and niche therapeutic APIs for regulated markets. Haleos Labs will provide manufacturing expertise, while HRV Global will contribute market access and regulatory capabilities.
Read the summary - Low impact
Haleos Labs: Special Window for Share Transfer Requests Closes with NIL Activity
Haleos Labs reports NIL activity for its 'Special Window' for re-lodgement of physical share transfer requests, which closed on January 6, 2026. No requests were received, processed, approved, or rejected during the window period.
Read the summary - Low impact
Haleos Labs Limited: SEBI Depositories Compliance Certificate for Q3 FY26
Haleos Labs Limited submitted a compliance certificate for Q3 FY26 as per SEBI regulations. The RT&TA confirmed timely processing of dematerialization requests and updating records for the period October 1 to December 31, 2025.
Read the summary - Low impact
Haleos Labs: Trading Window Closed Jan 1, 2026 for Q3 FY26 Results
Haleos Labs will close its trading window from January 1, 2026. This closure is in anticipation of the financial results for the quarter and nine months ending December 31, 2025. The window will reopen 48 hours after the results are declared.
Read the summary - Low impact
HALEOS LABS LIMITED Informs about Special Window for Re-lodgment of Transfer Requests
Haleos Labs Limited announced the opening of a "Special Window" for re-lodgment of transfer requests to its shareholders from July 7, 2025, to January 6, 2026, following SEBI guidelines.
Read the summary - Low impact
Haleos Labs Receives Demand Notice from Southern Power Distribution
Haleos Labs received a demand notice of ₹87.59 lakh from Southern Power Distribution for CSS amount from April 2015 to June 2016. The company will pursue legal remedies.
Read the summary - Low impact
HALEOS LABS LIMITED unveils new company logo
Haleos Labs Limited (formerly SMS Life Sciences India Limited) unveils its new company logo, approved by the board on November 25, 2025, to reflect its refreshed brand identity.
Read the summary - Low impact
HALEOS LABS LIMITED: Name and Symbol Change Effective November 26, 2025
Haleos Labs Limited (formerly SMS Lifesciences India Limited) announces a change in the company's name and stock symbol to "HALEOSLABS", effective November 26, 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio